morpheus matrix visualization and analysis software (Broad Institute Inc)
90
Structured Review
Broad Institute Inc
morpheus matrix visualization and analysis software
Morpheus Matrix Visualization And Analysis Software, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/matrix+analysis/morpheus+matrix+visualization+and+analysis+software/pmc10873754-33-22-27
Average 90 stars, based on 1 article reviews
Morpheus Matrix Visualization And Analysis Software, supplied by Broad Institute Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/matrix+analysis/morpheus+matrix+visualization+and+analysis+software/pmc10873754-33-22-27
Average 90 stars, based on 1 article reviews
morpheus matrix visualization and analysis software - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Generated:Article Title: Tape strip expression profiling of juvenile dermatomyositis skin reveals mitochondrial dysfunction contributing to disease endotype Article Snippet: .. Heatmaps were generated using the Article Title: Autophagy repression by antigen and cytokines shapes mitochondrial, migration and effector machinery in CD8 T cells Article Snippet: P values and fold changes for volcano plots were calculated using RStudio (v.2023.06.1+524) with the Bioconductor package ‘limma’ (v.3.54.2) . .. Heatmaps were generated using the Article Title: FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia Article Snippet: .. Heatmaps were generated using Article Title: Autophagy repression by antigen and cytokines shapes mitochondrial, migration and effector machinery in CD8 T cells. Article Snippet: P values and fold changes for volcano plots were calculated using RStudio (v.2023.06.1+524) with the Bioconductor package ‘limma’ (v.3.54.2)81. .. Heatmaps were generated using the Software:Article Title: Tape strip expression profiling of juvenile dermatomyositis skin reveals mitochondrial dysfunction contributing to disease endotype Article Snippet: .. Heatmaps were generated using the Article Title: CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Article Snippet: Hind Rafei, Rafet Basar, Sunil Acharya, Yu-Sung Hsu, Pinghua Liu, Deqiang Zhang, Toszka Bohn, Qingnan Liang, Vakul Mohanty, Ranjan Upadhyay, Ping Li, Pravin Phadatare, Merve Dede, Donghai Xiong, Huihui Fan, C orry Mathew Jones, Sebastian Kunz, May Daher, Ana Karen Nunez Cortes, Mayra Shanley, Bin Liu, Sadie Mae Moseley, Chenyu Zhang, Dexing Fang, Pinaki Banerjee, Nadima Uprety, Ye Li, Rejeena Shrestha, Xinhai Wan, Hong Shen, Vernikka Woods, A pr il Lamour Gilbert, Seema Rawal, Jinzhuang Dou, Yukun Tan, Jeong-Min Park, Francia Reyes Silva, A le xa nd er Biederstädt, Mecit Kaplan, Xin Ru Jiang, Inci Biederstädt, Bijender Kumar, Silvia Tiberti, Madison Moore, Jingling Jin, Ryan Z. Yang, Luis Muniz-Feliciano, Samuel Rosemore, Paul Lin, Gary M. Deyter, N at al ie Wall Fowlkes, Abhinav K. Jain, David Marin, Anirban Maitra, Ken Chen, Tobias Bopp, Elizabeth J. Shpall & Katayoun Rezvani1,2 ✉ Article Title: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Article Snippet: Outcomes of patients with CD30-positive (CD30) lymphomas have improved with the advent of brentuximab vedotin (BV) and, in Hodgkin lymphoma, anti-PD1 checkpoint inhibitors (CPI).. However, there is a need for new therapies for patients with tumors refractory to both BV and CPI, who face dismal outcomes.. AFM13—a CD30/CD16A bispecific antibody—activates natural killer (NK) cells to kill CD30 cells. Article Title: FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia Article Snippet: .. Heatmaps were generated using Article Title: Modeling the HLH immune synapse uncovers critical roles for IS termination, cytokine intensity, and target cell death. Article Snippet: Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening systemic hyperinflammatory syndrome arising in many contexts.. Its underlying mechanisms are often unclear, but defective granulemediated cytotoxicity (familial HLH) and excess IL-18 (Macrophage Activation Syndrome, MAS) provide clues.. Mounting evidence suggests the causes of HLH converge on cytotoxic T lymphocyte (CTL) hyperactivation and overproduction of IFNγ. Standard Deviation:Article Title: Tape strip expression profiling of juvenile dermatomyositis skin reveals mitochondrial dysfunction contributing to disease endotype Article Snippet: .. Heatmaps were generated using the Expressing:Article Title: CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Article Snippet: Hind Rafei, Rafet Basar, Sunil Acharya, Yu-Sung Hsu, Pinghua Liu, Deqiang Zhang, Toszka Bohn, Qingnan Liang, Vakul Mohanty, Ranjan Upadhyay, Ping Li, Pravin Phadatare, Merve Dede, Donghai Xiong, Huihui Fan, C orry Mathew Jones, Sebastian Kunz, May Daher, Ana Karen Nunez Cortes, Mayra Shanley, Bin Liu, Sadie Mae Moseley, Chenyu Zhang, Dexing Fang, Pinaki Banerjee, Nadima Uprety, Ye Li, Rejeena Shrestha, Xinhai Wan, Hong Shen, Vernikka Woods, A pr il Lamour Gilbert, Seema Rawal, Jinzhuang Dou, Yukun Tan, Jeong-Min Park, Francia Reyes Silva, A le xa nd er Biederstädt, Mecit Kaplan, Xin Ru Jiang, Inci Biederstädt, Bijender Kumar, Silvia Tiberti, Madison Moore, Jingling Jin, Ryan Z. Yang, Luis Muniz-Feliciano, Samuel Rosemore, Paul Lin, Gary M. Deyter, N at al ie Wall Fowlkes, Abhinav K. Jain, David Marin, Anirban Maitra, Ken Chen, Tobias Bopp, Elizabeth J. Shpall & Katayoun Rezvani1,2 ✉ Article Title: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Article Snippet: Outcomes of patients with CD30-positive (CD30) lymphomas have improved with the advent of brentuximab vedotin (BV) and, in Hodgkin lymphoma, anti-PD1 checkpoint inhibitors (CPI).. However, there is a need for new therapies for patients with tumors refractory to both BV and CPI, who face dismal outcomes.. AFM13—a CD30/CD16A bispecific antibody—activates natural killer (NK) cells to kill CD30 cells. Marker:Article Title: CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Article Snippet: Hind Rafei, Rafet Basar, Sunil Acharya, Yu-Sung Hsu, Pinghua Liu, Deqiang Zhang, Toszka Bohn, Qingnan Liang, Vakul Mohanty, Ranjan Upadhyay, Ping Li, Pravin Phadatare, Merve Dede, Donghai Xiong, Huihui Fan, C orry Mathew Jones, Sebastian Kunz, May Daher, Ana Karen Nunez Cortes, Mayra Shanley, Bin Liu, Sadie Mae Moseley, Chenyu Zhang, Dexing Fang, Pinaki Banerjee, Nadima Uprety, Ye Li, Rejeena Shrestha, Xinhai Wan, Hong Shen, Vernikka Woods, A pr il Lamour Gilbert, Seema Rawal, Jinzhuang Dou, Yukun Tan, Jeong-Min Park, Francia Reyes Silva, A le xa nd er Biederstädt, Mecit Kaplan, Xin Ru Jiang, Inci Biederstädt, Bijender Kumar, Silvia Tiberti, Madison Moore, Jingling Jin, Ryan Z. Yang, Luis Muniz-Feliciano, Samuel Rosemore, Paul Lin, Gary M. Deyter, N at al ie Wall Fowlkes, Abhinav K. Jain, David Marin, Anirban Maitra, Ken Chen, Tobias Bopp, Elizabeth J. Shpall & Katayoun Rezvani1,2 ✉ Article Title: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Article Snippet: Outcomes of patients with CD30-positive (CD30) lymphomas have improved with the advent of brentuximab vedotin (BV) and, in Hodgkin lymphoma, anti-PD1 checkpoint inhibitors (CPI).. However, there is a need for new therapies for patients with tumors refractory to both BV and CPI, who face dismal outcomes.. AFM13—a CD30/CD16A bispecific antibody—activates natural killer (NK) cells to kill CD30 cells. Real-time Polymerase Chain Reaction:Article Title: CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells. Article Snippet: Hind Rafei, Rafet Basar, Sunil Acharya, Yu-Sung Hsu, Pinghua Liu, Deqiang Zhang, Toszka Bohn, Qingnan Liang, Vakul Mohanty, Ranjan Upadhyay, Ping Li, Pravin Phadatare, Merve Dede, Donghai Xiong, Huihui Fan, C orry Mathew Jones, Sebastian Kunz, May Daher, Ana Karen Nunez Cortes, Mayra Shanley, Bin Liu, Sadie Mae Moseley, Chenyu Zhang, Dexing Fang, Pinaki Banerjee, Nadima Uprety, Ye Li, Rejeena Shrestha, Xinhai Wan, Hong Shen, Vernikka Woods, A pr il Lamour Gilbert, Seema Rawal, Jinzhuang Dou, Yukun Tan, Jeong-Min Park, Francia Reyes Silva, A le xa nd er Biederstädt, Mecit Kaplan, Xin Ru Jiang, Inci Biederstädt, Bijender Kumar, Silvia Tiberti, Madison Moore, Jingling Jin, Ryan Z. Yang, Luis Muniz-Feliciano, Samuel Rosemore, Paul Lin, Gary M. Deyter, N at al ie Wall Fowlkes, Abhinav K. Jain, David Marin, Anirban Maitra, Ken Chen, Tobias Bopp, Elizabeth J. Shpall & Katayoun Rezvani1,2 ✉ Transformation Assay:Article Title: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Article Snippet: Outcomes of patients with CD30-positive (CD30) lymphomas have improved with the advent of brentuximab vedotin (BV) and, in Hodgkin lymphoma, anti-PD1 checkpoint inhibitors (CPI).. However, there is a need for new therapies for patients with tumors refractory to both BV and CPI, who face dismal outcomes.. AFM13—a CD30/CD16A bispecific antibody—activates natural killer (NK) cells to kill CD30 cells. |
